New hope for 10x’ preliminary injunction after EPO Opposition Division ruling | Patent at issue concerns single-cell spatial ...

Buy 10x Genomics with a 1-year target of $12.7, projecting 18% growth. Read here for more on TXG stock's biopharma potential ...

In the microscopic world of bacteria, gene transfer is a powerful mechanism that can alter cellular function, drive antibiotic resistance and even shape entire ecosystems.

The 10 most innovative biotech companies of 2025 are leveraging AI to find new drugs, match patients with the best treatments ...

Two recent UPC decisions have provided some guidance on the admissibility and reasonableness of auxiliary requests in revocation actions. The ...

On February 12, 2025, the United States District Court for the District of Delaware denied defendant Parse Biosciences’s (“Parse”) motions for ...

Sand Hill Road Host Scott McGrew spoke with Jim Tananbaum to learn more about how artificial intelligence is fueling ...

Parse Biosciences affirms plans to proceed with development and future release of their Evercode™ single cell chromatin products.

10x Genomics has a fifty-two week low of $9.77 and a fifty-two week high of $45.60. The firm’s 50 day moving average price is $13.90 and its 200 day moving average price is $16.67. Get 10x ...

Woese Institute for Genomic Biology developed a CRISPR-enriched metagenomics method for the enhanced surveillance of antibiotic resistance genes, ARGs, in wastewater. While antibiotics are ...

As part of the agreement, Parse admitted that 10x Genomics' ATAC-seq patents are valid, enforceable, and had been infringed by Parse's use of ATAC-seq methods and compositions. Meanwhile ...